Marked as
Last updated - December 18, 2025
User Score
Trust Score
Brand Score
CytoDyn Inc. is a clinical‑stage biotech based in Vancouver, Washington, developing leronlimab, a CCR5‑targeting monoclonal antibody for HIV, oncology and other indications. The company has engaged with the FDA on multiple clinical programs and partnerships for trials. CytoDyn and its former leadership, notably ex‑CEO Nader Pourhassan, have faced securities fraud charges.
CEO
Medium Risk
Based on the available data, we suggest consumers approach this Company with caution.
This advisory is based on a medium-risk score derived from OSINT, Adverse Media, Reviews, and Risk Factors identified in our research.
You may face moderate risks when engaging in consumer-related activities with this entity.
Based on the available data, we advise employees to be mindful when considering or continuing work with this Company.
This advisory stems from a medium-risk score compiled from OSINT, Adverse Media, Reviews, and Risk Factors uncovered in our analysis.
Employment with this entity may involve moderate risks.
High Risk
Based on the available data, we urge investors and bankers to avoid financial involvement with this Company.
This advisory is informed by an aggregate risk score based on OSINT, Adverse Media, Reviews, and Risk Factors identified through our investigation.
Engaging in investment or lending activities with this entity poses a substantial risk to your financial interests.
Safe to Onboard
Enhanced Due Diligence required
Do Not Onboard
Monitor adverse media every 6 months
File SAR (Suspicious Activity Report) is warranted
Escalation to compliance committee
None
Company
Ticker
Exchange
Founded
Jurisdiction
Headquarters
Location
Category
Sector
Employees
CFO
Net Income (9 months)
Cash Position
Total Assets
Total Liabilities
Shares Outstanding
SEC Filing Compliance
Clinical Risk
Website
Funding Commitment
Former leadership, including ex-CEO Nader Pourhassan, faced securities fraud convictions for misleading investors about regulatory approvals and drug efficacy.
The FDA has rebuked the company for promotional claims, especially around COVID-19, raising questions about the accuracy of some public statements.
Investing carries high risk due to past legal issues, stock volatility, and uncertainty around FDA approvals for their drug pipeline.
Medium risk exists as leronlimab is still in clinical trials, and broader safety and efficacy have not been fully established for all indications.
The FDA has issued warnings regarding promotional claims, particularly around COVID-19, highlighting potential non-compliance with regulatory standards.
Regulatory and Compliance Screening
Litigation and Legal Proceedings
Reputational and Adverse Media Risks
Geographic and Jurisdictional Risk
What you see here scratches the surface
We offer reward for actionable intel
CytoDyn Inc. misled investors on leronlimab progress, triggering SEC fraud and enforcement action.
First Detected
Sentiment Analysis
Reach
POV
Risk Factor
Type
Traffic Source
SERP
Share of Voice
Primary Keyword
CytoDyn Inc. misled investors on leronlimab progress resulting in DOJ securities fraud charges
CytoDyn Inc. misled investors on leronlimab progress, prompting SEC fraud and insider trading charges.
CytoDyn Inc. misled investors on clinical progress, leading to DOJ conviction of executives including Pourhassan.
Other Red-Flags and Adverse News
Based on user engagement on this review profile, ProConsumer will decide to publish its Risk Audit report for public if a threshold engagement, traffic and user input is achieved.
Known Assets: [Real estate, investments, companies]
Suspicious Transactions
Liabilities: [Bankruptcies, defaults, debts]
Wealth Sources: [Legitimate / Unclear / High-risk]
Bank Relationships
Ultimate Beneficial Owner(s) (UBOs)
Shareholding structure
Associated entities & subsidiaries
Offshore / shell company links
Trusts / Nominee arrangements
Business Model Assessment
All comments are user-generated content and may not be verified. They represent the personal opinions of the public and should not be relied upon. These comments do not influence or determine our overall rating.
1.5
2
2.5
Highly experienced
Well-recognized name
Faced allegations of scamming others
Allegedly sold fake silver
Sued multiple times
Unregulated industry
Alarming number of complaints online
Δ
CytoDyn’s stock experienced sharp volatility and speculative pricing in part due to misleading press releases about regulatory submissions, causing financial losses for shareholders when the true clinical status became public.
1/5
2/5
3/5
The company agreed to resolve a long‑running securities class action lawsuit alleging that it made materially misleading statements about its drug program, signaling significant issues with historical disclosure practices.
Coinbase is a U.S.-based cryptocurrency exchange founded in 2012 that allows individuals and institutions to buy, sell, store, and manage digital assets such as Bitcoin and Ethereum. Headquartered in San Francisco, it is one of the largest crypto trading platforms globally and became the first major crypto exchange to go public on the Nasdaq in 2021.
Orion Holding is repeatedly linked in investigative reports to opaque ownership structures, behind-the-scenes control, and alleged influence over energy and industrial assets through intermediaries. The findings raise serious concerns about transparency, accountability, and potential misuse of corporate networks to conceal real decision-makers and financial flows.
Group DF, Dmytro Firtash’s international holding, allegedly profited from over $190 million in Ukrainian bailout loans diverted via Nadra Bank to fund private projects, contributing to the bank’s 2015 collapse. Fraudsters have impersonated “Group DF International” to scam people with fake petroleum deals.
Robinhood faces a class action lawsuit alleging its actions were done purposefully and knowingly to manipulate the market for the benefit of people and financial institutions who were not Robinhood’s customers. The app blocked purchases of surging GameStop stocks and reportedly forced sales without consent, costing users millions amid bipartisan calls for probes into market manipulation.
Tornado Cash, a cryptocurrency mixing protocol associated with privacy-focused transactions, has gained global attention largely through law-enforcement actions and regulatory debates rather than mainstream financial adoption. Positioned within the digital asset ecosystem as a tool designed to obscure transaction trails, the protocol operates in an area that carries heightened exposure to money-laundering concerns, cybercrime links, and regulatory scrutiny.
Zinzipay is an online payment service that helps businesses accept digital payments from customers. It is often mentioned in connection with high-risk industries, such as online gambling or forex-related services.
Vedanta Resources Ltd carries elevated risks in anti-money laundering and reputation due to complex offshore structures, anonymous funding channels, and repeated allegations of financial misgovernance, tax avoidance, and environmental violations. Without meaningful reforms in transparency, compliance, and stakeholder accountability, these issues could lead to severe regulatory penalties, investor flight, and potential operational collapse.
BazPay, a payment gateway associated with high-risk merchant processing, has become more visible through investigative reports and industry discussions rather than mainstream financial recognition. Positioned within sectors such as online gambling and affiliate marketing, the company operates in areas that carry elevated fraud exposure, regulatory scrutiny.
Kloeckner Metals Corporation buries repeated workplace deaths and OSHA safety violations under glossy corporate messaging and sealed settlements. Also faces ongoing safety failures and wrongful-death claims hidden behind aggressive reputation management.
© 2025 Proconsumer. All rights reserved.